Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2024-02-02 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于实际控制人兼董事长及其一致行动人增持股份计划的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding a shareholding increase plan by the company's actual controller and chairman, detailing the intent to increase shareholding within a specified period and amount. It includes information about the parties involved, the purpose, amount, price, implementation period, funding, and risks related to the share increase plan. This is a typical disclosure of a major shareholding change or planned increase by significant shareholders. It does not contain financial statements, audit information, or detailed financial results. It is not a report or presentation but a regulatory announcement about shareholding changes. Therefore, the appropriate classification is Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, confirming this classification with high confidence.
2024-02-02 Chinese
圣湘生物科技股份有限公司2023年年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2023 annual earnings forecast (业绩预告) for 圣湘生物科技股份有限公司, covering the full fiscal year from January 1, 2023 to December 31, 2023. It provides preliminary estimated financial results including revenue and net profit, with comparisons to the prior year. The document explicitly states that the financial data is unaudited and preliminary, and that the final audited results will be disclosed in the formal 2023 annual report. The document length is short (1565 characters) and it is a forward-looking earnings preview rather than a full financial report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and detailed analysis. Therefore, the correct classification is Earnings Release (ER). FY 2023
2024-01-22 Chinese
圣湘生物科技股份有限公司关于自愿披露相关产品取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of obtaining a medical device registration certificate for a specific product. It includes details about the product registration, its intended use, registration number, and the impact on the company. The document is relatively short (1057 characters) and does not contain financial statements or detailed financial analysis. It is an official announcement about a regulatory approval related to the company's product, not a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-01-03 Chinese
圣湘生物科技股份有限公司关于自愿披露相关产品取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of obtaining a medical device registration certificate for a new product. It includes details about the product, registration certificate, and its potential impact on the company. The document is short (1130 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is not an annual report, interim report, earnings release, or any detailed financial filing. It is an official announcement about a regulatory approval related to a product, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories like capital updates or management changes.
2023-12-27 Chinese
西部证券股份有限公司关于圣湘生物科技股份有限公司2023年度持续督导工作现场检查报告
Audit Report / Information Classification · 95% confidence The document is a report from 西部证券股份有限公司 (Western Securities Co., Ltd.) acting as the sponsor conducting an on-site inspection for the year 2023 regarding the continuous supervision of 圣湘生物科技股份有限公司 (Shengxiang Biotechnology Co., Ltd.). It details the sponsor's review of the company's governance, internal controls, information disclosure, independence, related party transactions, use of raised funds, guarantees, major investments, and operational status during the supervision period. The document includes findings, interviews, and verification of compliance with relevant laws and regulations, concluding that the company meets regulatory requirements. The document is titled as a "现场检查报告" (on-site inspection report) related to continuous supervision work, which aligns with an Audit Report / Information type filing rather than a full Annual Report or other categories. The document length is 2650 characters, which is relatively short but contains substantive content and detailed findings, not merely an announcement or certification. Therefore, it fits best under the Audit Report / Information (AR) category. FY 2023
2023-12-26 Chinese
圣湘生物科技股份有限公司第二届董事会2023年第十三次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a board meeting resolution by the company's board of directors. It details the approval of a restricted stock incentive plan and the granting of shares to incentive recipients. It includes meeting attendance, voting results, and references to related announcements on the stock exchange website. There is no financial report, earnings data, or detailed management discussion. The document is a formal announcement of board decisions, specifically about stock incentives, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report itself but a meeting resolution announcement, so it is not an Annual Report or Interim Report. Therefore, the correct classification is MANG with high confidence.
2023-12-25 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.